Innova Captab Limited

NSE INNOVACAP.NS

Innova Captab Limited Revenue for the year ending March 31, 2024: USD 129.12 M

Innova Captab Limited Revenue is USD 129.12 M for the year ending March 31, 2024, a 14.55% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Innova Captab Limited Revenue for the year ending March 31, 2023 was USD 112.71 M, a 7.01% change year over year.
  • Innova Captab Limited Revenue for the year ending March 31, 2022 was USD 105.33 M, a 88.31% change year over year.
  • Innova Captab Limited Revenue for the year ending March 31, 2021 was USD 55.93 M, a 12.91% change year over year.
  • Innova Captab Limited Revenue for the year ending March 31, 2020 was USD 49.54 M.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
SV Wall Street
NSE: INNOVACAP.NS

Innova Captab Limited

CEO Mr. Manoj Kumar Lohariwala
IPO Date Dec. 29, 2023
Location India
Headquarters SCO No. 301, Second Floor
Employees 1,600
Sector Healthcare
Industries
Description

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through its network of distributors and pharmacies, as well as online through various e-commerce pharmacy sites. The company was incorporated in 2005 and is based in Panchkula, India.

StockViz Staff

February 2, 2025

Any question? Send us an email